These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20649426)

  • 1. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
    Kim HN; Wang J; Hughes J; Coombs R; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Fuchs J; Eshleman SH; Khaki L; McMahon MA; Siliciano RF; Wald A; Celum C
    J Infect Dis; 2010 Sep; 202(5):734-8. PubMed ID: 20649426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
    Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.
    Watson-Jones D; Wald A; Celum C; Lingappa J; Weiss HA; Changalucha J; Baisley K; Tanton C; Hayes RJ; Marshak JO; Gladden RG; Koelle DM
    J Clin Microbiol; 2010 Oct; 48(10):3496-503. PubMed ID: 20702659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
    Van Wagoner N; Geisler WM; Bachmann LH; Hook EW
    Int J STD AIDS; 2015 Jul; 26(8):574-81. PubMed ID: 25147236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.
    Lingappa JR; Baeten JM; Wald A; Hughes JP; Thomas KK; Mujugira A; Mugo N; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife KH; de Bruyn G; Gray GE; McIntyre JA; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Magaret AS; Wang RS; Kidoguchi L; Barnes L; Ridzon R; Corey L; Celum C;
    Lancet; 2010 Mar; 375(9717):824-33. PubMed ID: 20153888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.
    Delany S; Mlaba N; Clayton T; Akpomiemie G; Capovilla A; Legoff J; Belec L; Stevens W; Rees H; Mayaud P
    AIDS; 2009 Feb; 23(4):461-9. PubMed ID: 19155993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
    Baeten JM; Lingappa J; Beck I; Frenkel LM; Pepper G; Celum C; Wald A; Fife KH; Were E; Mugo N; Sanchez J; Essex M; Makhema J; Kiarie J; Farquhar C; Corey L
    J Infect Dis; 2011 Jan; 203(1):117-21. PubMed ID: 21148504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
    Celum C; Wald A; Lingappa JR; Magaret AS; Wang RS; Mugo N; Mujugira A; Baeten JM; Mullins JI; Hughes JP; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife KH; de Bruyn G; Gray GE; McIntyre JA; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Stevens W; Campbell MS; Thomas KK; Coombs RW; Morrow R; Whittington WL; McElrath MJ; Barnes L; Ridzon R; Corey L;
    N Engl J Med; 2010 Feb; 362(5):427-39. PubMed ID: 20089951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.
    Cowan FM; Pascoe SJ; Barlow KL; Langhaug LF; Jaffar S; Hargrove JW; Robinson NJ; Bassett MT; Wilson D; Brown DW; Hayes RJ
    Sex Transm Infect; 2008 Dec; 84(7):548-53. PubMed ID: 18684855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
    Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
    N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
    Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
    J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.
    Mujugira A; Magaret AS; Celum C; Baeten JM; Lingappa JR; Morrow RA; Fife KH; Delany-Moretlwe S; de Bruyn G; Bukusi EA; Karita E; Kapiga S; Corey L; Wald A;
    J Infect Dis; 2013 Nov; 208(9):1366-74. PubMed ID: 23901094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.
    Zuckerman RA; Lucchetti A; Whittington WL; Sánchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
    AIDS; 2009 Feb; 23(4):479-83. PubMed ID: 19169140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.
    McMahon MA; Siliciano JD; Kohli RM; Siliciano RF
    AIDS; 2010 Jan; 24(2):319-23. PubMed ID: 20009920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.
    Mayaud P; Legoff J; Weiss HA; Grésenguet G; Nzambi K; Bouhlal H; Frost E; Pépin J; Malkin JE; Hayes RJ; Mabey DC; Bélec L;
    J Infect Dis; 2009 Jul; 200(2):216-26. PubMed ID: 19530940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes.
    LeGoff J; Weiss HA; Gresenguet G; Nzambi K; Frost E; Hayes RJ; Mabey DC; Malkin JE; Mayaud P; Belec L
    AIDS; 2007 Jul; 21(12):1569-78. PubMed ID: 17630552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
    Roxby AC; Drake AL; Ongecha-Owuor F; Kiarie JN; Richardson B; Matemo DN; Overbaugh J; Emery S; John-Stewart GC; Wald A; Farquhar C
    PLoS One; 2012; 7(6):e38622. PubMed ID: 22701683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
    Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
    J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines.
    Andersen-Nissen E; Chang JT; Thomas KK; Adams D; Celum C; Sanchez J; Coombs RW; McElrath MJ; Baeten JM
    Sex Transm Dis; 2016 Dec; 43(12):761-764. PubMed ID: 27832025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An addition to the effect of treating co-infections on HIV-1 viral load.
    Modjarrad K; Vermund SH
    Lancet Infect Dis; 2011 Feb; 11(2):81. PubMed ID: 21272789
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.